A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
515actual
Sites
119
Countries
Australia, Canada, China +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-11-13 | actual | When the study began enrolling |
| Primary completion | 2026-06-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-15 | estimated | The whole study's end, after follow-up |
| First posted | 2019-03-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- B-cell Non-Hodgkin Lymphoma (B-NHL)
Intervention
- Drug: Odronextamab — also filed as REGN1979
Primary outcomes
what the primary-completion date above is the date OFObjective Response Rate (ORR), as assessed by independent central review
measured Up to 52 weeks of study treatment
ORR, as assessed by independent central review
measured Up to 36 weeks of study treatment
Publications
- PMID 41766170 — linked by the registry
- PMID 40902079 — linked by the registry
- PMID 40472301 — linked by the registry
- PMID 40097657 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed